MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
Zentalis Pharmaceuticals ROA Ratio 2011-2026 | ZNTL
Annual ROA Ratio Zentalis Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -52.96 | -43.91 | -34.92 | -32.24 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -32.24 | -52.96 | -41.01 |
Quarterly ROA Ratio Zentalis Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -37.28 | -38.03 | -48.35 | -25.06 | -34.54 | -35.11 | -35.26 | -40.51 | -50.79 | -51.59 | -45.52 | -36.88 | -47.89 | -38.58 | -45.76 | -46.39 | -46.4 | -54.89 | -43.02 | -32.24 | -37.79 | -42.45 | -47.07 | -52.2 | -35.62 | -21.51 | -9.54 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -9.54 | -54.89 | -40.01 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
-123.72 | - | -10.17 % | $ 12.2 K |  USA |
 |
Aeglea BioTherapeutics
AGLE
|
-34.19 | - | - | $ 1.01 B | USA |
 |
Adagene
ADAG
|
-37.44 | $ 1.65 | 7.91 % | $ 92.9 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
-31.06 | $ 3.59 | 1.99 % | $ 8.64 B |  Australia |
 |
Arrowhead Pharmaceuticals
ARWR
|
-0.12 | $ 66.05 | 2.3 % | $ 8.83 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
-28.19 | $ 1.52 | -16.3 % | $ 388 M |  Britain |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M |  France |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
Biogen
BIIB
|
5.82 | $ 184.48 | -1.67 % | $ 26.9 B | USA |
 |
AVROBIO
AVRO
|
12.03 | - | 1083.1 % | $ 745 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
BioNTech SE
BNTX
|
65.02 | $ 102.17 | 2.32 % | $ 27.2 B | Germany |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M | Britain |
 |
AstraZeneca PLC
AZN
|
0.11 | $ 93.52 | -1.2 % | $ 96.9 B | Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
-86.4 | $ 4.25 | 1.67 % | $ 9.25 B |  Israel |
 |
BeiGene, Ltd.
BGNE
|
-10.89 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
-104.83 | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-43.36 | - | -7.31 % | $ 87 M | USA |
 |
Bristol-Myers Squibb Company
BMY
|
-9.66 | $ 55.71 | -0.28 % | $ 113 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
-35.36 | $ 207.49 | 2.22 % | $ 5 B |  Danmark |
 |
Codiak BioSciences
CDAK
|
-21.64 | - | -55.98 % | $ 2.15 M | USA |
 |
ARCA biopharma
ABIO
|
-21.14 | - | 1052.0 % | $ 415 M | USA |
 |
Cerevel Therapeutics Holdings
CERE
|
-34.81 | - | - | $ 7.29 B | USA |
 |
Acasti Pharma
ACST
|
-13.29 | - | 4.01 % | $ 150 M |  Canada |
 |
Zai Lab Limited
ZLAB
|
-21.68 | $ 18.37 | -0.97 % | $ 18.2 B | China |
 |
Coherus BioSciences
CHRS
|
-37.78 | $ 1.61 | -5.03 % | $ 152 M | USA |
 |
Catalyst Biosciences
CBIO
|
-73.35 | $ 10.84 | 0.46 % | $ 714 M | USA |
 |
Caladrius Biosciences
CLBS
|
-57.1 | - | -16.75 % | $ 25.8 M | USA |
 |
Celldex Therapeutics
CLDX
|
-19.92 | $ 25.59 | -6.54 % | $ 1.65 M | USA |
 |
Cellectis S.A.
CLLS
|
-32.74 | $ 4.22 | -4.2 % | $ 116 M | France |
 |
Clearside Biomedical
CLSD
|
-95.49 | - | - | $ 25.3 M | USA |
 |
Chimerix
CMRX
|
-38.58 | - | - | $ 756 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-40.29 | - | -15.15 % | $ 60.3 M | Britain |
 |
Corcept Therapeutics Incorporated
CORT
|
16.8 | $ 37.35 | -0.4 % | $ 3.86 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
19.25 | $ 23.18 | 2.02 % | $ 2.75 B | USA |
 |
AIkido Pharma
AIKI
|
-31.2 | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
-11.27 | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
-225.71 | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-20.15 | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-49.57 | - | 4.14 % | $ 49.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-20.8 | $ 55.11 | 3.49 % | $ 4.45 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-16.34 | $ 55.17 | 2.47 % | $ 4.65 B |  Schweiz |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M | Israel |
 |
Ampio Pharmaceuticals
AMPE
|
-150.49 | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
10.11 | $ 29.43 | 6.09 % | $ 1.43 B | USA |